Christopher Bunker

Company: Alamar Biosciences Inc.

Job title: Chief Business Officer

Seminars:

2:45 NULISA Neurology Biomarker Platform – Brain-derived pTau217 and High-plex Neurodegenerative Disease and Neuroinflammatory Biomarker Analysis 2:45 pm

NULISA™: Ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis First brain-derived (BD) pTau217 assay for highest accuracy blood-based Alzheimer's detection CNS Disease Panel: Unique in its coverage of hundreds of proteins involved in neurodegeneration, inflammation, vascular and synaptic dysfunction. New BD-Tau181,217, 231, total assays Inflammation Panel: Comprehensive coverage of cytokines and key immune markers…Read more

day: Conference Day 1